Status: Finalised
First registered on:
23/10/2014
Last updated on:
24/03/2015
1. Study identification
EU PAS Register NumberEUPAS7753
Official titleComparative effectiveness and safety of Ipramol (ipratropium/albuterol) SteriNebs® vs. DuoNeb®
Study title acronym
Study typeObservational study
Brief description of the studyHistoric cohort, US database study comparing effectiveness and safety of nebulised COPD medication labelled by Teva Ltd (Ipramol SteriNebs®) against the originator product (DuoNeb®)
Was this study requested by a regulator?Don't know
Is the study required by a Risk Management Plan (RMP)?
Regulatory procedure number (RMP Category 1 and 2 studies only)
Other study registration identification numbers and URLs as applicable
2. Research centres and Investigator details
Coordinating study entity
Centre to which the investigator belongsRIRL
Department/Research group
Organisation/affiliationResearch in Real Life Ltd.
Details of (Primary) lead investigator
Title Dr
Last name Mares
First name Rafael
Is this study being carried out with the collaboration of a research network?
No
Other centres where this study is being conducted
Not applicable (single centre)
Countries in which this study is being conducted
National study
United States
3. Study timelines: initial administrative steps, progress reports and final report
PlannedActual
Date when funding contract was signed07/05/201407/05/2014
Start date of data collection30/06/201407/07/2014
Start date of data analysis15/08/201419/09/2014
Date of interim report, if expected14/10/201414/10/2014
Date of final study report03/11/201403/11/2014
4. Sources of funding
Please provide estimates of the percentage of funding by source for this study
Names(s)Approximate % funding
Pharmaceutical companiesTeva100
Charities
Government body
Research councils
EU funding scheme
5. Contact details for enquiries
Scientific Enquiries
Title Professor
Last name Price
First name David
Address line 116 Raffles Quay
Address line 2#33-03
Address line 3Hong Leong Building
CitySingapore
Postcode048581
CountrySingapore
Phone number (incl. country code)44-1223-967829
Alternative phone number
Fax number (incl. country code)
Public Enquiries
Title Professor
Last name Price
First name David
Address line 116 Raffles Quay
Address line 2#33-03
Address line 3Hong Leong Building
CitySingapore
Postcode048581
CountrySingapore
Phone number (incl. country code)44-1223-967829
Alternative phone number
Fax number (incl. country code)
6. Study drug(s) information
Product NameIpramol Sterinebs
CountryUnited States
Substance INN(s)IPRATROPIUM BROMIDE
SALBUTAMOL SULFATE
Product NameDuoneb
CountryUnited States
Substance INN(s)IPRATROPIUM BROMIDE
SALBUTAMOL SULFATE
7. Medical conditions to be studied
Medical condition(s)Yes
Chronic obstructive pulmonary disease
8. Population under study
Age
Adults (18 - 44 years)
Adults (45 - 64 years)
Adults (65 - 74 years)
Adults (75 years and over)
Sex
Male
Female
9. Number of subjects
Estimated total number of subjects2142
Additional information
536 individuals in the Ipramol SteriNebs® cohort and 1,606 in the DuoNeb® cohort.
10. Source of data
Is this study being carried out with an established data source?Yes
Data sources not registered with ENCePP
Clinformatics™ Data Mart (CDM), United States
Sources of data
Administrative database, e.g. claims database
11. Scope of the study
What is the scope of the study?
Risk assessment
Effectiveness evaluation
Primary scope : Effectiveness evaluation
12. Main objective(s)
What is the main objective of the study?
The aim of this study is to compare Ipramol SteriNebs® with its originator, DuoNeb®. The primary objective is to assess whether effectiveness (in terms of
exacerbations) of Ipramol SteriNebs® is non-inferior to that of DuoNeb®.
Are there primary outcomes?Yes
The primary outcome of this study is "effectiveness", evaluated in terms of:
1. Severe COPD exacerbations (hospitalisations) in outcome period, and
2. Moderate and severe COPD exacerbations in outcome period
(Please see the attached protocol for full definitions of these outcomes)
Are there secondary outcomes?Yes
The secondary outcome of this study is "safety", evaluated in terms of:
Adverse Events (AEs). These will include AEs known to be related to Ipramol SteriNebs® and DuoNeb®, as specified in their respective summary of product characteristics. (Please see the attached protocol for detailed definition of this outcome)
13. Study design
What is the design of the study?
Cohort study
Historical cohort database study
14. Follow-up of patients
Will patients be followed up?Not applicable/no follow-up
15. Data analysis plan
Please provide a brief summary of the analysis method
Statistically significant results will be defined as p<0.05 and trends as 0.05<p<0.10. Summary statistics will be produced for all baseline and outcome variables by therapy. Treatment groups will be compared using t-test / Mann-Whitney U test (depending on distribution) for variables measured on the interval/ratio scale and using a chi square test for categorical variables.
Outcomes analyses: patients may be matched on demographics and key measures of disease severity to minimise confounding, using random selection process through SAS statistical software to avoid selection bias. Effectiveness and safety in the outcome period will be compared between treatment groups using a conditional Poisson regression model. The model will use empirical standard errors (for more conservative confidence interval estimations) and adjustments will be made for potential baseline confounders. The adjusted rate ratio with 95% confidence interval will be reported.
16. ENCePP seal
Are you requesting the ENCePP seal for this study?
No
17. Full protocol
18. Study Results
Not submitted
Please list the 5 most relevant publications using data from your study
ReferenceLink to web-publication
None
19. Other relevant documents
Conflict(s) of interest of
investigator(s)Not submitted
Composition of Steering Group and
ObserversNot submitted
Other documentsNot
submitted
Signed Code of
Conduct Checklist
Not submitted
Signed Code of Conduct Declaration
Not submitted
Signed Checklist for Study
Protocols
Not submitted
